ArticleThe AAPS journal2025
The Impact of Cognate Antigen Binding on the FcRn-mediated Transcytosis and Recycling of Monoclonal Antibodies.
Article in The AAPS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin G (IgG) antibodies rely on neonatal Fc receptor (FcRn)-mediated recycling and transcytosis for prolonged serum half-life and tissue distribution. However, high antigen loads during infection may alter FcRn-mediated trafficking, impacting therapeutic efficacy. This study investigates how cognate antigen binding influences FcRn-mediated transport of two SARS-CoV-2-specific (SCoV-2) monoclonal antibodies: Sotrovimab, an Fc-engineered antibody with enhanced FcRn affinity, and B38, a non-engineered comparator. We evaluated antibody binding using ELISA and bio-layer interferometry (BLI) and assessed FcRn-mediated transport through transcytosis and recycling assays in MDCK cells expressing human FcRn. Experiments were conducted with and without SCoV-2 wild-type (WT) spike protein (SP) at a 1:1 molar ratio. Sotrovimab demonstrated superior binding affinity to both SCoV-2 WT SP and FcRn, exhibiting greater baseline transcytosis and recycling efficiency. However, antigen presence significantly reduced transcytosis for both antibodies, with Sotrovimab showing a more pronounced decrease (46.7% vs. 23% for B38). Recycling responses also diverged: Sotrovimab showed a modest, non-significant decrease while recycling of B38 significantly increased. Kinetic analysis revealed antigen binding altered FcRn interactions differently. The higher binding affinity of Sotrovimab was due to reduced dissociation at neutral pH, potentially trapping complexes intracellularly. B38 showed faster association at pH 6.0 without compromised dissociation. These data suggest that cognate antigen binding and interaction of immune complexes (ICs) with FcRn, play a major role in influencing transcytosis and recycling of mAb. These findings emphasize the complex interplay between antigen binding and FcRn function, with implications for antibody dosing strategies during infection to optimize tissue distribution and efficacy.
Indexed as
Identifiers
41339598What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.